homovanillic acid has been researched along with Alcohol Abuse in 85 studies
Homovanillic Acid: A 3-O-methyl ETHER of (3,4-dihydroxyphenyl)acetic acid.
homovanillate : A hydroxy monocarboxylic acid anion which is obtained by deprotonation of the carboxy group of homovanillic acid.
homovanillic acid : A monocarboxylic acid that is the 3-O-methyl ether of (3,4-dihydroxyphenyl)acetic acid. It is a catecholamine metabolite.
| Excerpt | Relevance | Reference |
|---|---|---|
| " After chronic alcoholism, there was a decrease in the ratio of dihydroxyphenylacetic acid (DOPA) and homovanillic acid (HVA) to dopamine in the nucleus accumbens and striatum in rats subjected to alcoholism, as compared with intact controls." | 3.72 | Mechanisms of the influences of the central administration of substance P on ethanol consumption in chronically alcoholic rats. ( Bychkov, ER; Dambinova, SA; Lebedev, AA; Nikolaev, SV, 2003) |
| "Among treatment-seeking alcoholics, early age at onset is generally associated with a more severe course of alcoholism and lower cerebrospinal fluid 5-hydroxyindoleacetic acid concentration." | 3.69 | Early-onset alcoholics have lower cerebrospinal fluid 5-hydroxyindoleacetic acid levels than late-onset alcoholics. ( Brown, GL; Eckardt, MJ; Fils-Aime, ML; George, DT; Linnoila, M; Mefford, I, 1996) |
| "Among all offenders, low cerebrospinal fluid (CSF) 5-hydroxyindoleacetic acid (5-HIAA) and homovanillic acid (HVA) concentrations were associated with a family history positive for paternal alcoholism with violence." | 3.69 | A prospective follow-up study of alcoholic violent offenders and fire setters. ( Eggert, M; Linnoila, M; Rawlings, R; Virkkunen, M, 1996) |
| " There were significant, negative correlations between interview-derived lifetime aggression scores and cerebrospinal fluid concentrations of both the serotonin metabolite 5-hydroxyindoleacetic acid and the dopamine metabolite homovanillic acid." | 3.68 | Personality and cerebrospinal fluid monoamine metabolites in alcoholics and controls. ( Adinoff, B; Goldman, D; Lamparski, D; Limson, R; Linnoila, M; Ravitz, B; Roy, A, 1991) |
| " Recidivists who committed a new violent offense or arson had significantly lower cerebrospinal fluid 5-hydroxyindoleacetic acid and homovanillic acid concentrations and blood glucose nadirs after oral glucose challenge than did nonrecidivists." | 3.67 | Relationship of psychobiological variables to recidivism in violent offenders and impulsive fire setters. A follow-up study. ( Bartko, J; De Jong, J; Goodwin, FK; Linnoila, M; Virkkunen, M, 1989) |
| "5-Hydroxyindoleacetic acid (5-HIAA) and homovanillic acid (HVA) were measured in the spinal fluid of 45 women hospitalized in a psychiatric department for major depression (14 cases), schizophrenia (18 cases) and alcohol dependence (13 cases)." | 3.66 | Relationship between cerebrospinal fluid amine metabolites, neuroendocrine findings and personality dimensions (Marke-Nyman scale factors) in psychiatric patients. ( Arató, M; Banki, CM, 1983) |
| "5-Hydroxyindoleacetic acid (5-HIAA) and homovanillic acid (HVA) were measured in the lumbar cerebrospinal fluid of 57 drug-free female patients with DSM-III diagnoses of major unipolar or bipolar depression (n = 14), schizophrenic disorder (n = 18), alcohol dependence (n = 13) and a group of other disorders (n = 12)." | 3.66 | Amine metabolites and neuroendocrine responses related to depression and suicide. ( Arató, M; Banki, CM, 1983) |
| "Alcoholic, impulsive offenders with antisocial personality disorder had low mean cerebrospinal fluid (CSF) 5-hydroxyindoleacetic acid (5-HIAA) and corticotropin levels and high mean CSF testosterone concentrations." | 1.29 | CSF biochemistries, glucose metabolism, and diurnal activity rhythms in alcoholic, violent offenders, fire setters, and healthy volunteers. ( Bissette, G; Guidotti, A; Kalogeras, K; Karonen, SL; Linnoila, M; Nemeroff, C; Poland, RE; Rawlings, R; Tokola, R; Virkkunen, M, 1994) |
| "To explore dopaminergic mechanisms in alcohol dependence, the authors measured plasma homovanillic acid (HVA) in recently detoxified alcohol-dependent men." | 1.29 | Low plasma homovanillic acid levels in recently abstinent alcoholic men. ( Chae, Y; Fulton, MK; Isbell, PG; Kramer, G; Moeller, FG; Petty, F, 1995) |
| " Dose-response curves for DA and 5-HT release indicated no marked difference in the sensitivity to ethanol between the lines." | 1.28 | Ethanol enhances the release of dopamine and serotonin in the nucleus accumbens of HAD and LAD lines of rats. ( Li, TK; Lumeng, L; McBride, WJ; Yoshimoto, K, 1992) |
| "Severity of withdrawal symptoms assessed on a rating scale in 14 patients with 4 days or less of abstinence correlated marginally with HVA but not with 5-HIAA." | 1.26 | Factors influencing monoamine metabolites and tryptophan in patients with alcohol dependence. ( Banki, CM, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 35 (41.18) | 18.7374 |
| 1990's | 33 (38.82) | 18.2507 |
| 2000's | 16 (18.82) | 29.6817 |
| 2010's | 1 (1.18) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hirth, N | 1 |
| Meinhardt, MW | 1 |
| Noori, HR | 1 |
| Salgado, H | 1 |
| Torres-Ramirez, O | 1 |
| Uhrig, S | 1 |
| Broccoli, L | 1 |
| Vengeliene, V | 1 |
| Roßmanith, M | 1 |
| Perreau-Lenz, S | 1 |
| Köhr, G | 1 |
| Sommer, WH | 1 |
| Spanagel, R | 1 |
| Hansson, AC | 1 |
| Yoshimura, R | 1 |
| Nakano, W | 1 |
| Nakamura, K | 1 |
| Heinz, A | 1 |
| Jones, DW | 1 |
| Bissette, G | 3 |
| Hommer, D | 1 |
| Ragan, P | 1 |
| Knable, M | 1 |
| Wellek, S | 1 |
| Linnoila, M | 22 |
| Weinberger, DR | 1 |
| Nikolaev, SV | 2 |
| Bychkov, ER | 2 |
| Lebedev, AA | 2 |
| Dambinova, SA | 2 |
| Sher, L | 4 |
| Agartz, I | 1 |
| Shoaf, S | 1 |
| Rawlings, RR | 1 |
| Momenan, R | 1 |
| Hommer, DW | 1 |
| Köhnke, MD | 3 |
| Wiatr, G | 3 |
| Kolb, W | 3 |
| Köhnke, AM | 1 |
| Schick, S | 1 |
| Lutz, U | 2 |
| Vonthein, R | 1 |
| Gaertner, I | 1 |
| Ojanen, S | 1 |
| Koistinen, M | 1 |
| Bäckström, P | 1 |
| Kankaanpää, A | 1 |
| Tuomainen, P | 1 |
| Hyytiä, P | 1 |
| Kiianmaa, K | 1 |
| Oquendo, MA | 2 |
| Li, S | 1 |
| Huang, YY | 2 |
| Grunebaum, MF | 2 |
| Burke, AK | 2 |
| Malone, KM | 1 |
| Mann, JJ | 2 |
| Ponce, G | 1 |
| Hoenicka, J | 1 |
| Rodríguez-Jiménez, R | 1 |
| Gozalo, A | 1 |
| Jimenéz, M | 1 |
| Monasor, R | 1 |
| Aragüés, M | 1 |
| Rubio, G | 1 |
| Jiménez-Arriero, MA | 1 |
| Ramos, JA | 1 |
| Palomo, T | 1 |
| Ducci, F | 1 |
| Newman, TK | 1 |
| Funt, S | 1 |
| Brown, GL | 5 |
| Virkkunen, M | 8 |
| Goldman, D | 6 |
| Maurer, S | 2 |
| Batra, A | 2 |
| Lutz, UC | 1 |
| Machicao, F | 1 |
| Buchkremer, G | 1 |
| Quintanilla, ME | 1 |
| Bustamante, D | 1 |
| Tampier, L | 1 |
| Israel, Y | 1 |
| Herrera-Marschitz, M | 1 |
| Zarcone, VP | 1 |
| Schreier, L | 2 |
| Mitchell, G | 1 |
| Orenberg, E | 2 |
| Barchas, J | 2 |
| Carlsson, A | 1 |
| Adolfsson, R | 1 |
| Aquilonius, SM | 1 |
| Gottfries, CG | 1 |
| Oreland, L | 1 |
| Svennerholm, L | 1 |
| Winblad, B | 3 |
| Fujimoto, A | 1 |
| Rosenthal, NE | 1 |
| Davenport, Y | 1 |
| Cowdry, RW | 1 |
| Webster, MH | 1 |
| Goodwin, FK | 4 |
| Banki, CM | 6 |
| Molnar, G | 1 |
| Arató, M | 4 |
| Papp, Z | 2 |
| Kurcz, M | 1 |
| Sjöquist, B | 4 |
| Perdahl, E | 1 |
| Murphy, JM | 2 |
| McBride, WJ | 3 |
| Lumeng, L | 3 |
| Li, TK | 3 |
| Martin, PR | 1 |
| Ebert, MH | 1 |
| Gordon, EK | 1 |
| Kopin, IJ | 1 |
| Borg, S | 2 |
| Robins, AH | 1 |
| Barron, JL | 1 |
| Eriksson, A | 1 |
| Kvande, H | 1 |
| Rawlings, R | 5 |
| Tokola, R | 2 |
| Poland, RE | 1 |
| Guidotti, A | 2 |
| Nemeroff, C | 1 |
| Kalogeras, K | 1 |
| Karonen, SL | 1 |
| Hartleb, J | 1 |
| Eue, S | 1 |
| Kemper, A | 1 |
| George, T | 2 |
| Eckardt, M | 1 |
| Higley, JD | 3 |
| Nielsen, D | 1 |
| Sano, H | 2 |
| Suzuki, Y | 2 |
| Ohara, K | 4 |
| Miyasato, K | 1 |
| Yokoyama, T | 2 |
| Adamson, MD | 1 |
| Kennedy, J | 1 |
| Petronis, A | 1 |
| Dean, M | 2 |
| Blanchard, BA | 1 |
| Glick, SD | 1 |
| Hawley, RJ | 1 |
| Nemeroff, CB | 1 |
| Gabel, S | 1 |
| Stadler, J | 1 |
| Bjorn, J | 1 |
| Shindledecker, R | 1 |
| Bowden, CL | 1 |
| Fulton, MK | 1 |
| Kramer, G | 1 |
| Moeller, FG | 1 |
| Chae, Y | 1 |
| Isbell, PG | 1 |
| Petty, F | 1 |
| Fils-Aime, ML | 1 |
| Eckardt, MJ | 2 |
| George, DT | 5 |
| Mefford, I | 1 |
| Eggert, M | 1 |
| Howard, MO | 1 |
| Cowley, DS | 1 |
| Roy-Byrne, PP | 1 |
| Hopfenbeck, JR | 1 |
| Suomi, SJ | 2 |
| Moss, HB | 1 |
| Yao, JK | 1 |
| Lambert, G | 1 |
| Esler, M | 1 |
| Philpot, RM | 1 |
| Kirstein, CL | 1 |
| Hibbeln, JR | 1 |
| Umhau, JC | 1 |
| Salem, N | 1 |
| Phillips, MJ | 1 |
| Shoaf, SE | 1 |
| Petrakis, IL | 1 |
| Trevisan, L | 1 |
| D'Souza, C | 1 |
| Gil, R | 1 |
| Krasnicki, S | 1 |
| Webb, E | 1 |
| Heninger, G | 1 |
| Cooney, N | 1 |
| Krystal, JH | 1 |
| Lappalainen, J | 1 |
| Long, JC | 1 |
| Ozaki, N | 1 |
| Zarcone, V | 1 |
| Benson, K | 1 |
| Kato, N | 2 |
| Takahashi, S | 2 |
| Tani, N | 2 |
| Iwase, N | 1 |
| Odani, K | 1 |
| Terenius, L | 1 |
| Wahlström, A | 1 |
| Agren, H | 1 |
| Ballenger, JC | 2 |
| Major, LF | 2 |
| Zoghbi, F | 1 |
| Emerit, J | 1 |
| Fermanian, J | 1 |
| Bousquet, O | 1 |
| Legrand, JC | 1 |
| Mazzella, GL | 1 |
| Bo, P | 1 |
| Mola, M | 1 |
| Massarini, M | 1 |
| Gitlow, SE | 1 |
| Dziedzic, LM | 1 |
| Dziedzic, SW | 1 |
| Wong, BL | 1 |
| Bolos, AM | 1 |
| Diana, M | 2 |
| Gessa, GL | 3 |
| Rossetti, ZL | 2 |
| Yazaki, R | 1 |
| Ishigaki, T | 1 |
| Yoshimoto, K | 1 |
| Melis, F | 1 |
| Carboni, S | 1 |
| Roy, A | 5 |
| Lamparski, D | 3 |
| De Jong, J | 3 |
| Adinoff, B | 5 |
| Ravitz, B | 3 |
| Nutt, D | 1 |
| Nutt, DJ | 1 |
| Berrettini, W | 1 |
| Mefford, IN | 1 |
| Costa, E | 1 |
| Limson, R | 1 |
| Wahlström, G | 1 |
| Magnusson, O | 1 |
| Nordberg, A | 1 |
| Stenström, A | 1 |
| Tiger, G | 1 |
| DeJong, J | 2 |
| Fadda, F | 1 |
| Colombo, G | 1 |
| Degrell, I | 1 |
| Pék, G | 1 |
| Nagy, D | 1 |
| Nagy, E | 1 |
| Hoyer, S | 1 |
| Bartko, J | 1 |
| Lidberg, L | 1 |
| Tuck, JR | 1 |
| Asberg, M | 1 |
| Scalia-Tomba, GP | 1 |
| Bertilsson, L | 1 |
| Oliver, J | 1 |
| Potter, WZ | 1 |
| Varkov, AI | 1 |
| Malikova, LA | 1 |
| Yamane, H | 1 |
| Kondo, H | 1 |
| Angrist, B | 1 |
| Sathananthan, G | 1 |
| Wilk, S | 1 |
| Gershon, S | 1 |
| Roos, BE | 1 |
| Silfverskiöld, BP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double-Blind, Placebo-Controlled Study of Brexpiprazole in the Treatment of Borderline Personality Disorder.[NCT03418675] | Phase 2 | 80 participants (Actual) | Interventional | 2018-11-26 | Completed | ||
| The Better Resiliency Among Veterans With Omega-3's (BRAVO) Study: A Double Blind, Placebo-Controlled Trial of Omega-3 Fatty Acid Supplementation Among Military Veterans[NCT01901887] | Phase 1 | 125 participants (Actual) | Interventional | 2014-03-01 | Terminated (stopped due to low recruitment) | ||
| Ranger Resilience and Improved Performance on Phospholipid Bound Omega-3's[NCT02908932] | 555 participants (Actual) | Interventional | 2016-08-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
A clinician-administered assessment of anxiety that will be assessed at all study visits (Visit 1-Visit 8). Changes in scores from baseline to final visit will be assessed. Higher scores (up to 56) indicate higher levels of anxiety, with 0 being no symptoms of anxiety. (NCT03418675)
Timeframe: assessed at Visits 1 to 8, change in scores from Visit 1 to Visit 8 (baseline to Week 12) is reported
| Intervention | change in score on a scale (Mean) |
|---|---|
| Placebo | -2.41 |
| Rexulti | -4.88 |
A clinician-administered assessment of depression that will be assessed at all study visits (Visits 1-8). Higher total scores indicate higher levels of depression (up to 52), while a score of 0 would indicate no depressive symptoms. (NCT03418675)
Timeframe: Assessed at Visits 1 to 8, change in scores from Visit 1 to Visit 8 (baseline to week 12) is reported
| Intervention | change in score on a scale (Mean) |
|---|---|
| Placebo | -2.09 |
| Rexulti | -3.81 |
A self-report assessment of impulsivity that will be assessed at baseline and visit 8. The BIS is composed of 30 items describing common impulsive or non-impulsive (for reverse scored items) behaviors and preferences. Items are scored on a 4-point scale: (Rarely/Never = 1, Occasionally = 2, Often = 3, Almost Always/Always = 4). These scores are summed to produce an overall impulsivity score ranging from 30 (not impulsive) to 120 (extremely impulsive). (NCT03418675)
Timeframe: Baseline (Visit 1), Week 12 (Visit 8)
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Visit 1 | Visit 8 | |
| Placebo | 76.53 | 68.13 |
| Rexulti | 72.27 | 70.5 |
A self rated scale used to measure severity and change. The first 12 items of the scale are on a scale from 1-5, with 5 meaning that the item caused extreme distress, severe difficulties in relationships, and/or kept them from getting things done. The lowest rating (1) means it caused little or no problems. Items 13-15 (positive behaviors) are rated according to frequency. Completed at every visit. (NCT03418675)
Timeframe: Assessed at Visits 1 to 8, change in scores from Visit 1 to Visit 8 (baseline to week 12) is reported
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Visit 1 | Visit 8 | |
| Placebo | 40.90 | 29.15 |
| Rexulti | 40.54 | 23.15 |
"A self-report scale measuring suicidality. Subjects will complete the scale at all visits. Subjects are asked about suicidal thoughts. If answers are no, rater can proceed to suicidal behavior section where subject is asked about any non-suicidal self injurious behavior. If yes, subject is asked about intensity of ideations. In the event of serious threat to themselves, the subject will be escorted to the emergency room. Total score indicates severity of suicidal ideation and behavior, with lower scores representing lower levels of suicidality and higher scores representing higher levels of suicidality. A score of 0 would reflect no suicidality present, whereas a maximum score of 5 would reflect active suicidal ideation with intent to act." (NCT03418675)
Timeframe: Baseline (Visit 1), Week 12 (Visit 8)
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Visit 1 | Visit 8 | |
| Placebo | 1.15 | 0.23 |
| Rexulti | 0.73 | 0.08 |
A short-structured interview that assesses comorbid psychiatric disorders according to the DSM 5 criteria. This assessment will be done during the baseline visit. (NCT03418675)
Timeframe: Baseline (Week 1)
| Intervention | Participants (Count of Participants) | ||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Major Depressive Episode (Current) | Major Depressive Episode (Past) | Manic Episode (Current) | Manic Episode (Past) | Hypomanic Episode (Current) | Bipolar I Disorder (Current) | Bipolar I Disorder (Past) | Bipolar II Disorder (Current) | Bipolar II Disorder (Past) | Panic Disorder (Current) | Panic Disorder (Lifetime) | Agoraphobia (Current) | Social Anxiety Disorder (Current) | Obsessive Compulsive Disorder (Current) | Post Traumatic Stress Disorder (Current) | Alcohol Use Disorder (Past 12 months) | Substance Use Disorder (Past 12 months) | Any Psychotic Disorder (Current) | Any Psychotic Disorder (Lifetime) | Major Depressive Disorder with Psychotic Features (Current) | Major Depressive Disorder with Psychotic Features (Past) | Anorexia Nervosa (current) | Bulimia Nervosa (Current) | Binge Eating Disorder (Current) | Generalized Anxiety Disorder (Current) | Antisocial Personality Disorder (Lifetime) | ADHD Combined Type (Current) | ADHD Inattentive Type (Current) | ADHD Hyperactive Type (Current) | Tourette's Syndrome (Lifetime) | Persistent Motor Tic Disorder (Lifetime) | Provisional Vocal Tic Disorder (Lifetime) | Provisional Tic Disorder (Lifetime) | Specific Phobia | Body Dysmorphic Disorder (Current) | |
| Placebo | 16 | 12 | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 6 | 11 | 7 | 6 | 3 | 9 | 13 | 11 | 0 | 0 | 0 | 0 | 0 | 4 | 2 | 10 | 8 | 2 | 0 | 1 | 0 | 1 | 0 | 0 | 4 | 3 |
| Rexulti | 18 | 18 | 2 | 3 | 0 | 0 | 0 | 0 | 1 | 6 | 10 | 9 | 9 | 3 | 12 | 8 | 8 | 0 | 1 | 0 | 0 | 1 | 4 | 4 | 15 | 4 | 4 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 2 |
A self-report assessment of patient perceived quality of life that will be assessed at baseline and visit 8. Higher scores indicate a higher quality of life, whereas lower scores indicate a lower quality of life. Participants are asked to rate the importance of each domain on a 3-point scale ranging from 1=not important to 3=very important, and to rate how satisfied they are with that domain on a 6-point scale, ranging from -3=very dissatisfied to +3=very satisfied. In scoring, importance ratings are multiplied by satisfaction ratings to produce weighted satisfaction scores for each of the 16 domains. Weighted satisfaction scores are summed and divided by the number of domains that were rated as important or very important to produce a raw score, which is then converted to a t-score, which provides a proxy measurement for perceived quality of life. T-scores range from very low perceived quality of life (0-36) to high perceived quality of life (58-77). (NCT03418675)
Timeframe: Baseline (Week 1), Week 12 (Visit 8)
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Visit 1 | Visit 8 | |
| Placebo | 28.89 | 30.75 |
| Rexulti | 28.70 | 35.71 |
A self-report scale assessing Borderline Personality severity that will be assessed at all visits.This scale is assessing severity and change in BPD symptoms. This is a 9-item scale measuring severity of different aspects of Borderline Personality Disorder, with each item rated on a 0-4 scale, 0=no symptoms, 4=severe symptoms. Total scores range from 0-36. (NCT03418675)
Timeframe: Baseline (Visit 1), Week 1 (Visit 2), Week 2 (Visit 3), Week 4 (Visit 4), Week 6 (Visit 5), Week 8 (Visit 6), Week 10 (Visit 7), Week 12 (Visit 8)
| Intervention | score on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Visit 1 | Visit 2 | Visit 3 | Visit 4 | Visit 5 | Visit 6 | Visit 7 | Visit 8 | |
| Placebo | 18.2 | 12.8 | 10.7 | 10.7 | 9.7 | 9.6 | 8.7 | 9.3 |
| Rexulti | 17.6 | 10.9 | 7.9 | 8.0 | 7.0 | 6.6 | 6.0 | 5.8 |
Subjects will complete the SDS at all visits. The change in scores from baseline to study completion will be assessed. The scale itself assesses the level of disability from borderline personality disorder (or target disorder) with higher scores indicating a more debilitating disorder. Scores range from 0-30. (NCT03418675)
Timeframe: Baseline (Visit 1), Week 1 (Visit 2), Week 2 (Visit 3), Week 4 (Visit 4), Week 6 (Visit 5), Week 8 (Visit 6), Week 10 (Visit 7), Week 12 (Visit 8)
| Intervention | score on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Visit 1 | Visit 2 | Visit 3 | Visit 4 | Visit 5 | Visit 6 | Visit 7 | Visit 8 | |
| Placebo | 17.3 | 13.3 | 11.5 | 12.4 | 11.7 | 11.2 | 12.0 | 12.7 |
| Rexulti | 15.8 | 10.7 | 7.8 | 7.8 | 7.0 | 7.9 | 6.9 | 7.7 |
An instrument that helps evaluate a broad range of psychological problems and symptoms of Borderline Personality Disorder psychopathology. This will be assessed at baseline and visit 8.The 115 items are rated by using a 5-step Likert scale (0=not at all, 4=very strong) and provide a global picture of borderline psychopathology. Global scores of borderline psychopathology are calculated by summing 12 items and range from 0-48. Higher scores indicate more severe symptoms of Borderline Personality Disorder. (NCT03418675)
Timeframe: Baseline, Visit 8 (Week 12)
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Visit 1 | Visit 8 | |
| Placebo | 26.17 | 20.25 |
| Rexulti | 25.42 | 14.21 |
A clinician-administered scale assessing Borderline Personality Scale severity at all study visits. Scores range from 0-36. Higher scores represent worse Borderline Personality Disorder severity, and lower scores represent milder Borderline Personality Disorder severity. (NCT03418675)
Timeframe: Baseline (Visit 1), Week 1 (Visit 2), Week 2 (Visit 3), Week 4 (Visit 4), Week 6 (Visit 5), Week 8 (Visit 6), Week 10 (Visit 7), Week 12 (Visit 8)
| Intervention | score on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Visit 1 | Visit 2 | Visit 3 | Visit 4 | Visit 5 | Visit 6 | Visit 7 | Visit 8 | |
| Placebo | 14.9 | 7.6 | 4.7 | 6 | 4.2 | 5.7 | 5 | 8.4 |
| Rexulti | 14.9 | 6.7 | 5.3 | 4.4 | 4.5 | 4.9 | 4 | 3.1 |
2 reviews available for homovanillic acid and Alcohol Abuse
| Article | Year |
|---|---|
Serotonin, violent behavior and alcohol.
Topics: Age Factors; Alcoholism; Animals; Biomarkers; Finland; Homovanillic Acid; Humans; Hydroxyindoleaceti | 1994 |
Alcoholism and suicide.
Topics: Adult; Age Factors; Alcoholism; Depressive Disorder; Female; Glucose; Homovanillic Acid; Humans; Hyd | 1986 |
3 trials available for homovanillic acid and Alcohol Abuse
| Article | Year |
|---|---|
Effects of clonidine on central and peripheral catecholamine metabolism.
Topics: Aged; Alcoholism; Blood Pressure; Clonidine; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Ma | 1984 |
The effect of disulfiram on the urinary excretion of catecholamine metabolites in alcoholic males.
Topics: Adult; Alcoholism; Disulfiram; Epinephrine; Homovanillic Acid; Humans; Male; Metanephrine; Middle Ag | 1983 |
Buspirone treatment of alcoholism: age of onset, and cerebrospinal fluid 5-hydroxyindolacetic acid and homovanillic acid concentrations, but not medication treatment, predict return to drinking.
Topics: Adult; Age of Onset; Alcoholism; Anti-Anxiety Agents; Buspirone; Double-Blind Method; Homovanillic A | 1999 |
80 other studies available for homovanillic acid and Alcohol Abuse
| Article | Year |
|---|---|
Convergent evidence from alcohol-dependent humans and rats for a hyperdopaminergic state in protracted abstinence.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Aged; Alcohol Abstinence; Alcoholism; Animals; Benzazepines; | 2016 |
[Alcoholism and depression: catecholamines and brain-derived neurotrophic factors].
Topics: Adult; Aged; Alcoholism; Antidepressive Agents; Biomarkers; Brain-Derived Neurotrophic Factor; Catec | 2009 |
Relationship between cortisol and serotonin metabolites and transporters in alcoholism [correction of alcolholism].
Topics: Adult; Affect; Alcoholism; Carrier Proteins; Case-Control Studies; Corticotropin-Releasing Hormone; | 2002 |
[The influence of substance P central administration on ethanol intake in rats chronically exposed to alcohol].
Topics: 3,4-Dihydroxyphenylacetic Acid; Alcohol Drinking; Alcoholism; Animals; Corpus Striatum; Dopamine; Dr | 2002 |
Alcoholism, violence, and CSF HVA. Cerebrospinal fluid homovanillic acid.
Topics: Alcoholism; Homovanillic Acid; Humans; Violence | 2003 |
CSF monoamine metabolites and MRI brain volumes in alcohol dependence.
Topics: Adult; Alcoholism; Biogenic Monoamines; Brain; Female; Homovanillic Acid; Humans; Magnetic Resonance | 2003 |
Plasma homovanillic acid: a significant association with alcoholism is independent of a functional polymorphism of the human catechol-O-methyltransferase gene.
Topics: Adult; Alcohol Withdrawal Delirium; Alcoholism; Analysis of Variance; Catechol O-Methyltransferase; | 2003 |
Differential behavioural sensitization to intermittent morphine treatment in alcohol-preferring AA and alcohol-avoiding ANA rats: role of mesolimbic dopamine.
Topics: 3,4-Dihydroxyphenylacetic Acid; Alcoholism; Animals; Chromatography, High Pressure Liquid; Dopamine; | 2003 |
Lower CSF homovanillic acid levels in depressed patients with a history of alcoholism.
Topics: Adult; Alcoholism; Case-Control Studies; Chi-Square Distribution; Chromatography, High Pressure Liqu | 2003 |
Major depressive disorder and a past history of alcoholism.
Topics: Alcoholism; Comorbidity; Depressive Disorder, Major; Homovanillic Acid; Humans | 2003 |
Mechanisms of the influences of the central administration of substance P on ethanol consumption in chronically alcoholic rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Alcohol Drinking; Alcoholism; Animals; Dopamine; Ethanol; Homovanill | 2003 |
IDRD2 TaqIA polymorphism is associated with urinary homovanillic acid levels in a sample of Spanish male alcoholic patients.
Topics: Adolescent; Adult; Aged; Alcoholism; Alleles; Biogenic Monoamines; Chromatography, High Pressure Liq | 2004 |
CSF monoamine metabolites and lethality of suicide attempts in depressed patients with alcohol dependence.
Topics: Adult; Alcoholism; Biogenic Monoamines; Depression; Female; Homovanillic Acid; Humans; Hydroxyindole | 2007 |
A functional polymorphism in the MAOA gene promoter (MAOA-LPR) predicts central dopamine function and body mass index.
Topics: Alcoholism; Body Mass Index; Crime; Dopamine; Finland; Genotype; Homovanillic Acid; Humans; Hydroxyi | 2006 |
Allele distribution of a monoamine oxidase A gene promoter polymorphism in German alcoholics and in subgroups with severe forms of alcohol withdrawal and its influence on plasma homovanillic acid.
Topics: Alcoholism; Alleles; Germany; Homovanillic Acid; Humans; Monoamine Oxidase; Promoter Regions, Geneti | 2006 |
Significant impact of MTHFR C677T polymorphism on plasma homovanillic acid (HVA) levels among alcohol-dependent patients.
Topics: Adult; Alcoholism; Alleles; Dopamine; Female; Genetic Carrier Screening; Genotype; Homocysteine; Hom | 2007 |
Dopamine release in the nucleus accumbens (shell) of two lines of rats selectively bred to prefer or avoid ethanol.
Topics: 3,4-Dihydroxyphenylacetic Acid; Alcohol Drinking; Alcoholism; Anesthesia, Inhalation; Animals; Breed | 2007 |
Sleep variables, cyclic AMP and biogenic amine metabolites after one day of ethanol ingestion.
Topics: Adult; Alcohol Drinking; Alcoholism; Cyclic AMP; Ethanol; Homovanillic Acid; Humans; Hydroxyindoleac | 1980 |
Biogenic amines in human brain in normal aging, senile dementia, and chronic alcoholism.
Topics: 5-Methoxytryptamine; Adult; Aged; Aging; Alcoholism; Brain; Dementia; Dopamine; Homovanillic Acid; H | 1980 |
[Cerebrospinal fluid monamine metabolites and cyclic nucleotides during alcoholic withdrawal syndrome].
Topics: Adult; Alcoholism; Brain; Cyclic AMP; Cyclic GMP; Female; Homovanillic Acid; Humans; Hydroxyindoleac | 1980 |
Monoamine metabolites in cerebrospinal fluid of depressive subgroups.
Topics: Adult; Alcoholism; Bipolar Disorder; Depressive Disorder; Female; Glycols; Homovanillic Acid; Humans | 1980 |
Factors influencing monoamine metabolites and tryptophan in patients with alcohol dependence.
Topics: Alcoholism; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Kinetics; Phenylacetates; R | 1981 |
The influence of age, height, and body weight on cerebrospinal fluid amine metabolites and tryptophan in women.
Topics: Adult; Age Factors; Alcoholism; Body Height; Body Weight; Depressive Disorder; Female; Homovanillic | 1981 |
Relationship between cerebrospinal fluid amine metabolites, neuroendocrine findings and personality dimensions (Marke-Nyman scale factors) in psychiatric patients.
Topics: Alcoholism; Bipolar Disorder; Depressive Disorder; Dexamethasone; Female; Homovanillic Acid; Humans; | 1983 |
Amine metabolites and neuroendocrine responses related to depression and suicide.
Topics: Alcoholism; Depression; Depressive Disorder; Dexamethasone; Female; Homovanillic Acid; Humans; Hydro | 1983 |
The effect of dexamethasone on cerebrospinal fluid monoamine metabolites and cortisol in psychiatric patients.
Topics: Adult; Aged; Alcoholism; Bipolar Disorder; Depressive Disorder; Dexamethasone; Female; Homovanillic | 1983 |
Cerebrospinal fluid biochemical examinations: do they reflect clinical or biological differences?
Topics: Adult; Aged; Alcoholism; Bipolar Disorder; Calcium; Depressive Disorder; Dexamethasone; Female; Homo | 1983 |
The effect of alcoholism on salsolinol and biogenic amines in human brain.
Topics: Alcoholism; Biogenic Amines; Brain; Caudate Nucleus; Dopamine; Homovanillic Acid; Humans; Hydroxyind | 1983 |
Monoamine and metabolite levels in CNS regions of the P line of alcohol-preferring rats after acute and chronic ethanol treatment.
Topics: 3,4-Dihydroxyphenylacetic Acid; Alcoholic Intoxication; Alcoholism; Animals; Brain Chemistry; Choice | 1983 |
Catecholamines and metabolites in cerebrospinal fluid of teetotallers and sober alcoholics.
Topics: Adult; Age Factors; Alcohol Drinking; Alcoholism; Catecholamines; Dopamine; Homovanillic Acid; Human | 1984 |
Salsolinol and catecholamines in human brain and their relation to alcoholism.
Topics: Adult; Alcoholism; Animals; Autopsy; Brain; Brain Chemistry; Catecholamines; Dopamine; Homovanillic | 1982 |
Catecholamine derived compounds in urine and cerebrospinal fluid from alcoholics during and after long-standing intoxication.
Topics: Adult; Aged; Alcoholic Intoxication; Alcoholism; Catecholamines; Dopamine; Female; Homovanillic Acid | 1981 |
CSF biochemistries, glucose metabolism, and diurnal activity rhythms in alcoholic, violent offenders, fire setters, and healthy volunteers.
Topics: Adrenocorticotropic Hormone; Adult; Alcoholism; Antisocial Personality Disorder; Circadian Rhythm; D | 1994 |
Simultaneous analysis of homovanillic acid, 5-hydroxyindoleacetic acid, 3-methoxy-4-hydroxyphenylethylene glycol and vanilmandelic acid in plasma from alcoholics by high-performance liquid chromatography with electrochemical detection. Critical comparison
Topics: Alcohol Withdrawal Delirium; Alcoholism; Biogenic Monoamines; Chromatography, High Pressure Liquid; | 1993 |
Circadian variations in plasma monoamine metabolites level in alcoholic patients: a possible predictor of alcohol withdrawal delirium.
Topics: Adult; Alcohol Withdrawal Delirium; Alcoholism; Analysis of Variance; Biogenic Monoamines; Circadian | 1994 |
DRD4 dopamine receptor genotype and CSF monoamine metabolites in Finnish alcoholics and controls.
Topics: Adult; Alcoholism; Alleles; Amines; Base Sequence; Finland; Homovanillic Acid; Humans; Male; Molecul | 1995 |
Sex differences in mesolimbic dopamine responses to ethanol and relationship to ethanol intake in rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Alcohol Drinking; Alcoholism; Animals; Arousal; Corpus Striatum; Dos | 1995 |
Neurochemical correlates of sympathetic activation during severe alcohol withdrawal.
Topics: Adult; Aged; Alcohol Withdrawal Delirium; Alcoholism; Arousal; Carrier Proteins; Corticotropin-Relea | 1994 |
Monoamine oxidase and homovanillic acid in boys with predispositions to substance abuse.
Topics: Adolescent; Alcoholism; Antisocial Personality Disorder; Child; Child of Impaired Parents; Fathers; | 1994 |
Low plasma homovanillic acid levels in recently abstinent alcoholic men.
Topics: Alcohol Drinking; Alcoholism; Dopamine; Homovanillic Acid; Hospitalization; Humans; Male; Sensitivit | 1995 |
Early-onset alcoholics have lower cerebrospinal fluid 5-hydroxyindoleacetic acid levels than late-onset alcoholics.
Topics: Adult; Age of Onset; Alcohol Drinking; Alcoholism; Comorbidity; Family; Female; Homovanillic Acid; H | 1996 |
A prospective follow-up study of alcoholic violent offenders and fire setters.
Topics: Adult; Alcoholism; Cholesterol; Comorbidity; Criminal Law; Family; Finland; Firesetting Behavior; Fo | 1996 |
Tridimensional personality traits in sons of alcoholic and nonalcoholic fathers.
Topics: Adult; Alcoholism; Arousal; Blood Platelets; Child of Impaired Parents; Homovanillic Acid; Humans; M | 1996 |
A nonhuman primate model of type II excessive alcohol consumption? Part 1. Low cerebrospinal fluid 5-hydroxyindoleacetic acid concentrations and diminished social competence correlate with excessive alcohol consumption.
Topics: Adult; Affect; Age Factors; Alcohol Drinking; Alcoholism; Animals; Arousal; Disease Models, Animal; | 1996 |
A nonhuman primate model of type II alcoholism? Part 2. Diminished social competence and excessive aggression correlates with low cerebrospinal fluid 5-hydroxyindoleacetic acid concentrations.
Topics: Adult; Age Factors; Aggression; Alcohol Drinking; Alcoholism; Animals; Antisocial Personality Disord | 1996 |
Associations of beta-endorphin with HVA and MHPG in the plasma of prepubertal boys: effects of familial drug abuse and antisocial personality disorder liability.
Topics: Alcoholism; Antisocial Personality Disorder; beta-Endorphin; Child; Child of Impaired Parents; Fathe | 1996 |
Origin of homovanillic acid in plasma.
Topics: Alcoholism; Brain; Dopamine; Homovanillic Acid; Humans | 1997 |
The effects of repeated alcohol exposure on the neurochemistry of the periadolescent nucleus accumbens septi.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aging; Alcoholism; Animals; Dopamine; Dose-Response Relationship, Dr | 1998 |
Essential fatty acids predict metabolites of serotonin and dopamine in cerebrospinal fluid among healthy control subjects, and early- and late-onset alcoholics.
Topics: Adult; Age of Onset; Alcoholism; Biomarkers; Case-Control Studies; Cholesterol; Cross-Sectional Stud | 1998 |
Essential fatty acids predict metabolites of serotonin and dopamine in cerebrospinal fluid among healthy control subjects, and early- and late-onset alcoholics.
Topics: Adult; Age of Onset; Alcoholism; Biomarkers; Case-Control Studies; Cholesterol; Cross-Sectional Stud | 1998 |
Essential fatty acids predict metabolites of serotonin and dopamine in cerebrospinal fluid among healthy control subjects, and early- and late-onset alcoholics.
Topics: Adult; Age of Onset; Alcoholism; Biomarkers; Case-Control Studies; Cholesterol; Cross-Sectional Stud | 1998 |
Essential fatty acids predict metabolites of serotonin and dopamine in cerebrospinal fluid among healthy control subjects, and early- and late-onset alcoholics.
Topics: Adult; Age of Onset; Alcoholism; Biomarkers; Case-Control Studies; Cholesterol; Cross-Sectional Stud | 1998 |
CSF monoamine metabolite and beta endorphin levels in recently detoxified alcoholics and healthy controls: prediction of alcohol cue-induced craving?
Topics: Adult; Alcoholism; Behavior, Addictive; Biogenic Monoamines; Biomarkers; Case-Control Studies; Ethan | 1999 |
HTR2C Cys23Ser polymorphism in relation to CSF monoamine metabolite concentrations and DSM-III-R psychiatric diagnoses.
Topics: Alcoholism; Biogenic Monoamines; Brain; Dopamine; Genes; Genotype; Homovanillic Acid; Humans; Hydrox | 1999 |
Alcohol, sleep and cerebrospinal fluid changes in alcoholics: cyclic AMP and biogenic amine metabolites in CSF.
Topics: Adult; Alcoholism; Biogenic Amines; Cyclic AMP; Ethanol; Homovanillic Acid; Humans; Hydroxyindoleace | 1977 |
Changes in the metabolism of biogenic amines in alcoholism--especially regarding CSF monoamine metabolites and serum DBH activity.
Topics: Adult; Aged; Alcoholism; Biogenic Amines; Dopamine beta-Hydroxylase; Female; Homovanillic Acid; Huma | 1979 |
Naloxone (Narcan) treatment in depression: clinical observations and effects on CSF endorphins and monoamine metabolites.
Topics: Adult; Alcoholism; Biogenic Amines; Depression; Endorphins; Female; Homovanillic Acid; Humans; Hydro | 1977 |
Alcohol and central serotonin metabolism in man.
Topics: Adult; Alcoholism; Brain; Dopamine; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Male; Middl | 1979 |
Cerebrospinal fluid homovanillic acid in male alcoholics: effects of disulfiram.
Topics: Adult; Alcoholism; Disulfiram; Homovanillic Acid; Humans; Male; Middle Aged; Phenylacetates | 1977 |
Comparative study of urinary excretion rates of para-hydroxy-mandelic acid, homovanillic acid, vanylmandelic acid in cirrhotic patients with and without encephalopathy.
Topics: Aged; Alcoholism; Female; Hepatic Encephalopathy; Homovanillic Acid; Humans; Hydroxy Acids; Liver Ci | 1977 |
[Preliminary study of CSF levels of HVA in chronic alcoholics].
Topics: Adult; Alcoholism; Brain; Catecholamines; Homovanillic Acid; Humans; Male; Middle Aged; Phenylacetat | 1976 |
Influence of ethanol on human catecholamine metabolism.
Topics: Adult; Alcoholism; Brain; Epinephrine; Ethanol; Homovanillic Acid; Humans; Male; Metanephrine; Middl | 1976 |
D2 dopamine receptor genotype and cerebrospinal fluid homovanillic acid, 5-hydroxyindoleacetic acid and 3-methoxy-4-hydroxyphenylglycol in alcoholics in Finland and the United States.
Topics: Adult; Alcoholism; Alleles; Ethnicity; Finland; Genotype; Homovanillic Acid; Humans; Hydroxyindoleac | 1992 |
Lack of tolerance to ethanol-induced stimulation of mesolimbic dopamine system.
Topics: 3,4-Dihydroxyphenylacetic Acid; Alcoholic Intoxication; Alcoholism; Animals; Corpus Striatum; Dopami | 1992 |
Circadian variation in plasma homovanillic acid level during and after alcohol withdrawal in alcoholic patients.
Topics: Adult; Alcohol Withdrawal Delirium; Alcoholism; Circadian Rhythm; Dopamine; Homovanillic Acid; Human | 1992 |
Ethanol enhances the release of dopamine and serotonin in the nucleus accumbens of HAD and LAD lines of rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Alcoholism; Animals; Dopamine; Dose-Response Relationship, Drug; Eth | 1992 |
Alcohol withdrawal in rats is associated with a marked fall in extraneuronal dopamine.
Topics: 3,4-Dihydroxyphenylacetic Acid; Alcohol Withdrawal Delirium; Alcoholism; Animals; Corpus Striatum; D | 1992 |
Cerebrospinal fluid monoamine metabolites in alcoholic patients who attempt suicide.
Topics: Adult; Alcoholism; Biogenic Monoamines; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Methoxy | 1990 |
A cerebrospinal fluid study of the pathophysiology of panic disorder associated with alcoholism.
Topics: Adult; Alcoholism; Anxiety Disorders; beta-Endorphin; Diazepam Binding Inhibitor; Fear; Homovanillic | 1990 |
Personality and cerebrospinal fluid monoamine metabolites in alcoholics and controls.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Aggression; Alcoholism; Homovanillic Acid; Humans; Hydroxyind | 1991 |
Temporal studies of the inhibition of voluntary ethanol intake in the rat induced by intermittent ethanol treatment and some long term neurochemical consequences.
Topics: 3,4-Dihydroxyphenylacetic Acid; Alcohol Drinking; Alcoholism; Animals; Brain; Brain Mapping; Dopamin | 1991 |
Cerebrospinal fluid variables among alcoholics lack seasonal variation.
Topics: Adult; Alcoholism; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Male; Methoxyhydroxy | 1991 |
Genetic sensitivity to effect of ethanol on dopaminergic system in alcohol preferring rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Alcoholism; Animals; Brain; Caudate Nucleus; Dopamine; Ethanol; Fron | 1991 |
Depression among alcoholics. Relationship to clinical and cerebrospinal fluid variables.
Topics: Adult; Age Factors; Alcohol Drinking; Alcoholism; Anxiety Disorders; Depressive Disorder; Divorce; D | 1991 |
Dementias, psychological tests, and neurotransmitters.
Topics: Aged; Alcoholism; Alzheimer Disease; Dementia; Diagnosis, Differential; Female; Homovanillic Acid; H | 1985 |
Contents of monoamines in forebrain regions of alcohol-preferring (P) and -nonpreferring (NP) lines of rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Alcohol Drinking; Alcoholism; Animals; Biogenic Amines; Brain; Cereb | 1987 |
Relationship of psychobiological variables to recidivism in violent offenders and impulsive fire setters. A follow-up study.
Topics: Adult; Alcoholism; Blood Glucose; Criminal Psychology; Depressive Disorder; Disruptive, Impulse Cont | 1989 |
Homicide, suicide and CSF 5-HIAA.
Topics: Adult; Aggression; Alcoholism; Homicide; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Male; | 1985 |
High correlations of norepinephrine, dopamine, and epinephrine and their major metabolite excretion rates.
Topics: Adult; Alcoholism; Circadian Rhythm; Depressive Disorder; Dopamine; Epinephrine; Female; Homovanilli | 1988 |
[Catecholamine content of the rat brain at different stages of experimental alcoholism].
Topics: Alcoholism; Animals; Brain; Corpus Striatum; Dopamine; Homovanillic Acid; Humans; Hypothalamus; Male | 1985 |
CSF monoamine metabolites in alcoholism: a comparative study with depression.
Topics: Adult; Aged; Alcoholism; Depression; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Ma | 1974 |
Amphetamine psychosis: behavioral and biochemical aspects.
Topics: Adolescent; Adult; Affect; Alcoholism; Amphetamine; Brain; Cognition Disorders; Delusions; Depressio | 1974 |
Homovanillic acid in cerebrospinal fluid of alcoholics.
Topics: Adolescent; Adult; Aged; Alcoholism; Homovanillic Acid; Humans; Middle Aged; Phenylacetates; Wernick | 1973 |